No Data
Discover Alpha Tau Medical And 2 Other US Penny Stocks
Express News | Alpha Tau Announces Acceptance Into Fda’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha Dart® for Patients With Recurrent Glioblastoma Multiforme
H.C. Wainwright Maintains Alpha Tau Medical(DRTS.US) With Buy Rating, Maintains Target Price $9
Alpha Tau Treats First Patient With Recurrent Lung Cancer, In A Clinical Trial At Hadassah Medical Center In Jerusalem, Israel
Express News | Alpha Tau Announces FDA Approval of Ide to Initiate Multi-Center Investigator-Initiated Study of Alpha Dart® in Immunocompromised Patients With Recurrent Cscc
Alpha Tau Medical's Alpha DaRT Technology Shows Breakthrough Results in Cancer Trials | NASDAQ:DRTS
No Data
No Data